GOLGA6L22

Across TCGA pan-cancer cohorts, GOLGA6L22 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GOLGA6L22 data layer compared with 13 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher GOLGA6L22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GOLGA6L22 expression acts as an unfavorable survival marker.

ESCA and SARC are the cancer types where GOLGA6L22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.164	0.702	.001	21	view →
SARC	DFS	Median	All	0.109	0.632	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

GOLGA6L22–ESCA (OS)

Open the ESCA breakdown →